Fair Value Calculator Fair Value Calculator
EN DE

HLK Biotech Holding (AMHD) Fair Value & Analysis

Healthcare · US · Market cap $925

HB HLK Biotech Holding logo HLK Biotech Holding AMHD · US
Price$0.0002
Fair Value$0.0002
Upside+0.0%
Quality45/100
Watch HLK Biotech Holding for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range $0.0002 – $0.0002

Fair value as of: Jun 26, 2026

From 2 valuation models · updated 7 days ago

Fair value updated Jun 26, 2026 — revised from $0.0500 to $0.0002 (−99.6%) since Jun 24, 2026.

Price vs Fair Value (12 months)

$0.0002 $0.0002 Fair Value $0.0002 Jul 2025 Jul 2026

12‑month range $0.0002 – $0.0002 · the $0.0002 price screens below the $0.0002 fair value. As of Jun 26, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

HLK Biotech Holding (AMHD) currently trades at $0.0002, while our model-based Fair Value estimate is $0.0002 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

HLK Biotech Holding Group, Inc., through its subsidiaries, produces and sells biodiesel. It also acquires real estate properties. The company was formerly known as Amelot Holdings, Inc. and changed its name to HLK Biotech Holding Group, Inc. in February 2018. HLK Biotech Holding Group, Inc. is headquartered in Norfolk, Virginia.

Revenue & earnings trend

FY1997 – FY2016 · reported fiscal years

HLK Biotech Holding reported revenue of $8.3K in FY2016 versus $0 in FY1997. Reported net income was −$3.8K in FY2016.

Revenue
FY97 $0
FY98 $0
FY14 $18.1K
FY15 $12.2K
FY16 $8.3K
Net income
FY97 −$962K
FY98 −$1.0M
FY14 −$19.1K
FY15 $1
FY16 −$3.8K

Is AMHD fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 1276 HK$57.85 HK$29.84 -48%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,782 ₹915.92 -49%
Zoetis Inc Z1TS34 R$24.45 R$6.33 -74%
Hansoh Pharmaceutical Group 3692 HK$29.32 HK$23.94 -18%
Divi's Laboratories Limited DIVISLAB ₹6,623 ₹1,461 -78%
Swedish Orphan Biovitrum AB SOBI kr 446.60 kr 234.19 -48%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is HLK Biotech Holding (AMHD) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0002 versus a price of $0.0002 — about +0% (undervalued). Model-based estimate, not financial advice.
What is the fair value of AMHD?
Our model-based fair value for HLK Biotech Holding is $0.0002 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0002.
What is the quality score of AMHD?
HLK Biotech Holding has a Quality Score of 45/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the net profit margin of AMHD?
The net profit margin of HLK Biotech Holding is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.